NSE · Healthcare · Drug Manufacturers - Specialty & Generic
| Holder | Stake |
|---|---|
| Motilal Oswal Financial Services Ltd | 3.32% |
| ICICI Prudential Multicap Fund | 2.02% |
| Jagdish N Master | 1.41% |
| Document | Date |
|---|---|
| Q1 FY27 earnings call GUFIC BIOSCIENCES LIMITED – Q1 FY27 SUMMARY HEADLINE NUMBERS • Total revenue from operations Q1 FY27: INR 260.8 crores (vs INR 226.9 crores in Q1 FY | 2026-08-21 |
| Investor presentation · Q1 FY27 GUFIC BIOSCIENCES LIMITED – Q1 FY27 INVESTOR SUMMARY HEADLINE NUMBERS • Total Revenue Q1 FY27: Rs 260.8 crore (up from Rs 226.9 crore in Q1 FY26; +1 | 2026-08-14 |
| Quarterly results · Q1 FY27 GUFIC BIOSCIENCES LIMITED – QUARTERLY RESULTS SUMMARY Q1 FY2026-27 (Quarter Ended June 30, 2026) --- HEADLINE NUMBERS • Revenue from operations (St | 2026-08-14 |
| Annual report FY2026 GUFIC BIOSCIENCES LIMITED – FY 2025-26 SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Revenue from Operations (Standalone): ₨94,047.53 Lakhs in FY | 2026-08-12 |
| Quarterly results · Q4 FY26 GUFIC BIOSCIENCES LIMITED – FINANCIAL RESULTS SUMMARY Year Ended March 31, 2026 --- HEADLINE NUMBERS • Total Revenue (Standalone): Rs. 94,047.54 la | 2026-05-29 |
| Q3 FY26 earnings call DOCUMENT SUMMARY: GUFIC BIOSCIENCES LIMITED HEADLINE NUMBERS • No financial figures, revenue, earnings, or performance metrics provided in this docum | 2026-02-20 |
| Quarterly results · Q3 FY26 GUFIC BIOSCIENCES LIMITED – DOCUMENT SUMMARY HEADLINE NUMBERS • Q3 FY2026 Revenue (Standalone): Rs. 23,109.36 lakhs • 9M FY2026 Revenue (Standalone) | 2026-02-13 |
| Investor presentation GUFIC BIOSCIENCES LIMITED – Q3 FY26 INVESTOR SUMMARY --- HEADLINE NUMBERS • Q3 FY26 Total Revenue: Rs 231.1 crore (vs Rs 230.4 crore in Q2 FY26; vs | 2026-02-13 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | ₹0.10 / share ex-date Aug 28, 2026 | 2026-08-28 |
| Dividend | ₹0.10 / share ex-date Sep 22, 2025 | 2025-09-22 |
| Announcement | Date |
|---|---|
| Acquisition of another business completed Gufic Biosciences Limited, an Indian pharmaceutical company, announced Board approval on August 14, 2026 to incorporate a new subsidiary in the Philippines called Gufic Philippines Inc. The | 2026-08-14 |
| Further investment in Saraswat Co-operative Bank Limited Gufic Biosciences Limited has informed the Exchange about further investment in Saraswat Co-operative Bank Limited | 2026-05-29 |
| Acquisition of Gufic Biosciences Limited announced Gufic Biosciences Limited has informed the Exchange about Acquisition | 2026-02-13 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Gufic Biosciences Limited — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.